Excellent research, very interesting company with only 225M shares. Management owns 60%, very attractive when compared to the 1 B shares by almost all other OZ medical cannabis stocks.
does EMD generate cash from data sales to sustain its expenses?
one correction please about the pipeline diagram, Zelira has already got approval from TGA about two drugs. It has a total of 5 products being sold at the moment in Auatralia and US targeting insomnia.
the Q1 report due in 3 weeks will show how much money they have generated. By the end of 2021 Zleira will 15 approved drug in Australia, UK , Germany and some US states.
EMD Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
